Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 22, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares, specifically regarding the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
The primary material change reported is a reduction in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of October 21, 2004, the fund's holdings decreased from 18,973,304 to 18,909,706 shares. This movement occurred at an average price of $41.15 per share.
Outlook and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It notes that two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund in the same capacity as other employees or former employees.
Key Facts for Investor Verification
- Shareholding Change: The US Retirement Savings Plan reduced its ADR holdings by 63,598 shares.
- Transaction Price: The average price for the movement was $41.15.
- Director Involvement: Directors Dr. J.P. Garnier and Dr. T. Yamada have potential interests in the fund's holdings.
- Financial Data: No operational or financial performance metrics are included in this specific filing.